NCT03425149已完成1 期
A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Rate of subjects with solicited adverse events including injection site and systemic reactions
研究概览
简要总结
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated ZIKV vaccine. Each dose will be administered intramuscularly (i.m.) in the deltoid muscle on Days 0 and 28. In addition, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
only dedicated site staff responsible for handling including preparation and administration of the vaccine will be unblinded
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is 18 to 49 years of age on the day of screening (Visit 0);
- •Subject has a Body Mass Index (BMI) of ≥18.5 and <30 kg/m2 on the day of screening (Visit 0);
- •Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;
- •Subject is generally healthy as determined by the Investigator's clinical judgment based on medical history, physical examination and screening laboratory tests;
- •If subject is of childbearing potential:
- •i. Subject has a negative serum pregnancy test at screening (Visit 0);
- •ii. Subject agrees to employ adequate birth control measures for the duration of the study. This includes one of the following measures:
- •Hormonal contraceptives (e.g. implants, birth control pills, patches) since ≥30 days prior to first vaccination;
- •Intrauterine device;
- •Barrier type of birth control measure (e.g. condoms, diaphragms, cervical caps);
- •Vasectomy in the male sex partner ≥3 months prior to first vaccination;
排除标准
- •Subject has a history of known flavivirus infection, or vaccination with a licensed or investigational flavivirus vaccine;
- •Subject has plans to receive a licensed flavivirus vaccine during the course of the study;
- •Subject has plans to travel to areas (including within the US) with active ZIKV, Japanese Encephalitis Virus (JEV), Dengue Virus (DENV) or Yellow Fever Virus (YFV) transmission during the course of the study or has travelled to a flavivirus-endemic area within 4 weeks prior to study enrollment;
- •Subject is seropositive to ZIKV, JEV, DENV or West Nile virus (WNV);
- •Subject has received an inactivated vaccine within 2 weeks or live vaccine within 4 weeks prior to vaccination in this study;
- •Subject has clinically significant abnormal laboratory values, as determined by the Investigator, at screening (Visit 0);
- •Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);
- •Subject currently has or has a history of significant cardiovascular, respiratory (including asthma), metabolic, neurological (including Guillain-Barré syndrome), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder;
- •Subject has a disease or is undergoing a form of treatment or was undergoing a form of treatment within 4 weeks prior to study enrollment (i.e. subject randomized) that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800 μg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs (use of inhaled (low dose), intranasal or topical steroids is permitted);
- •Subject has a history of severe hypersensitivity reactions or anaphylaxis;
- •Subject has a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications);
- •Subject had acute febrile infections within two weeks prior to vaccination in this study;
- •Subject has donated blood within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or plans to donate blood or use blood products during the course of the study;
- •Subject has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating;
- •Subject is currently enrolled or has participated in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP or investigational device during the course of this study;
- •Subject has plans to become pregnant during the course of the study, or is pregnant (positive serum pregnancy test at screening) or lactating at the time of study enrollment;
- •Subject has a known or suspected problem with alcohol or drug abuse as determined by the Investigator;
- •Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
- •Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study;
- •Subject has any condition that, in the opinion of the Investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study.
结局指标
主要结局
Rate of subjects with solicited adverse events including injection site and systemic reactions
时间窗: within 7 days after any vaccination
次要结局
- Rate of subjects with serious adverse events (SAEs)(up to Day 208)
- Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination(28 days after last active vaccination)
- GMT for ZIKV-specific neutralizing antibody titer after first vaccination(Day 208 after first vaccination)
- Rate of subjects with solicited adverse events including injection site and systemic reactions(within 7 days after each vaccination)
- Rate of subjects with any IMP-related SAEs(up to Day 208)
- Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline(28 after last active vaccination)
- Rate of subjects with any adverse events (AEs)(during the entire study period, i.e., up to Day 208)
- Rate of subjects with any IMP-related AEs(up to Day 208)
- Rate of subjects with seroconversion after first vaccination(208 days after first vaccination)
- Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline(208 days after first vaccination)
- Rate of subjects with seroconversion after last active vaccination(28 days after last active vaccination)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule StudyZikaNCT02937233Kathryn Stephenson36
已完成
1 期
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.Zika Virus InfectionNCT02963909National Institute of Allergy and Infectious Diseases (NIAID)75
已完成
1 期
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected AdultsHIV InfectionsNCT03205917International AIDS Vaccine Initiative29
已完成
1 期
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected AdultsHIV InfectionNCT02960581International AIDS Vaccine Initiative48
已完成
1 期
Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)Ebola VirusNCT02269423Merck Sharp & Dohme LLC39